Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.
Ovarian cancer remains the leading cause of death among women with gynecologic malignancies, and the fifth leading cause of cancer mortality in women in the United States. Although many patients respond to first-line platinum-based therapy, most will experience disease recurrence. The role of further therapy in the setting of recurrent ovarian cancer is palliative, and large randomized phase III trials on treatment options for recurrent ovarian cancer are rare. Controversies exist as to the optimal timing and duration of treatment, and many issues regarding treatment of recurrent disease remain.
Liu
Joyce
J
Department of Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. ursula_matulonis@dfci.harvard.edu
Matulonis
Ursula
U
D000971:Antineoplastic Combined Chemotherapy Protocols; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000517:prevention & control; D017671:Platinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000633:toxicity*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence
D017671:Platinum Compounds